Semi-solid Cadotril Composition Crystalline Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diarrhea treatments, particularly those containing cadotril compounds, face challenges with stability, bioavailability, and side effects due to hydrolysis and surfactant-related issues, lacking effective semi-solid formulations and combination products with simethicone for gastro intestinal tract disorders.
Innovation Solution
Development of a semi-solid composition comprising cadotril, such as racecadotril, in combination with liquid-lipids and/or propylene glycol, which forms a crystalline structure enhancing bioavailability and allowing for controlled release, minimizing side effects and enabling co-administration with simethicone for improved therapeutic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liquid formulations comprising cadotril compounds are used, then bioavailability and absorption are improved, but the formulations lack sustained or controlled release capabilities
Solution Approach 1:
The patent changes the physical state parameter of cadotril from liquid to semi-solid formulation, creating a crystalline structure that provides both high bioavailability and controlled release. The semi-solid state allows for sustained release while maintaining the absorption benefits of liquid formulations.
Solution Approach 2:
The patent creates a composite semi-solid formulation combining cadotril with specific excipients (liquid-lipids and/or propylene glycol) that form a crystalline structure. This composite material achieves both rapid absorption and controlled release properties simultaneously.
2Object-generated harmful factors
If conventional diarrhea treatments are used, then symptom relief is achieved, but side effects and stability problems occur due to hydrolysis
Solution Approach 1:
The patent converts the harmful hydrolysis reaction into a beneficial controlled release mechanism. The crystalline structure formed in the semi-solid formulation allows for controlled hydrolysis of cadotril, providing sustained release while minimizing side effects and improving stability.
Solution Approach 2:
The patent changes the physical and chemical parameters of cadotril by forming a crystalline structure in a semi-solid matrix. This structural change protects the active ingredient from premature hydrolysis while allowing controlled release, thereby improving both stability and reducing side effects.
3Reliability
If higher doses of cadotril are administered to achieve therapeutic window, then efficacy is improved, but potential side effects increase
Solution Approach 1:
The patent changes the delivery parameter by creating a semi-solid formulation with controlled release properties. This allows for lower doses to achieve the same therapeutic effect, thereby reducing side effects while maintaining efficacy through sustained release.
Solution Approach 2:
The patent ensures continuous useful action through controlled release of cadotril from the semi-solid formulation. The sustained release mechanism maintains therapeutic levels over time, allowing for lower initial doses while achieving and maintaining the therapeutic window, thus reducing side effects.
4Reliability
If semi-solid formulations are developed to improve bioavailability, then absorption is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent simplifies manufacturing by focusing on parameter changes in the formulation process - specifically creating a crystalline structure through controlled cooling and mixing. This approach maintains high bioavailability while using straightforward manufacturing steps involving heating, mixing, and cooling.
Solution Approach 2:
The patent applies local quality by creating a crystalline structure with specific properties within the semi-solid matrix. The crystalline regions provide enhanced bioavailability and controlled release, while the overall formulation maintains ease of manufacture through simple mixing and cooling processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The semi-solid composition achieves increased bioavailability and controlled release of cadotril, reducing dosing frequency and minimizing side effects, while allowing for high doses with fast and prolonged effects, addressing the limitations of existing formulations.
Implementation Method 1
such a composition creates a special crystalline structure during manufacturing, which will give rise to a high surface area, which is substantially free from water
Implementation Method 2
mixing racecadotril with one or more suitable liquid solvent excipients, heating the mixture and mixing to dissolve cadotril, such as racecadotril
Implementation Method 3
Formulating racecadotril in an oil base or other suitable water free liquids as mentioned below provides protection from hydrolysis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a semi-solid composition comprising at least one cadotril and at least one liquid-lipid and/or polyol and/or glycerol and/or propylene glycol excipient, a dose unit comprising the semi-solid composition as well as use and a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract.